CN Patent

CN109689103A — 用于抑制5-ht2b激动剂的形成的制剂及其使用方法

Assigned to Zogenix International Ltd · Expires 2019-04-26 · 7y expired

What this patent protects

公开了药物组合物及其用途。第一药物与第二药物组合施用。第一药物如芬氟拉明的特征在于具有已知不良副作用的、包括如去乙芬氟拉明的5‑HT 2B 激动剂的代谢物形成。第二药物为如大麻二酚的CYP抑制剂的形式，其向下调节代谢物的形成，从而使第一药物更安全。

USPTO Abstract

公开了药物组合物及其用途。第一药物与第二药物组合施用。第一药物如芬氟拉明的特征在于具有已知不良副作用的、包括如去乙芬氟拉明的5‑HT 2B 激动剂的代谢物形成。第二药物为如大麻二酚的CYP抑制剂的形式，其向下调节代谢物的形成，从而使第一药物更安全。

Drugs covered by this patent

fenfluramine-hydrochloride (FENFLURAMINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN109689103A
Jurisdiction: CN
Classification: —
Expires: 2019-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Zogenix International Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.